ImmunoCellular Therapeutics, Ltd
23622 Calabasas Road
Suite 300
Calabasas
California
91302
United States
Tel: 818-264-2300
Fax: 818-224-5287
Website: http://www.imuc.com/
278 articles about ImmunoCellular Therapeutics, Ltd
-
EOM PHARMACEUTICAL HOLDINGS, INC. ANNOUNCES NAME CHANGE FROM IMMUNOCELLULAR THERAPEUTICS, LTD.
11/10/2022
EOM Pharmaceutical Holdings, Inc. ("EOM"), a clinical-stage pharmaceutical company, today announced its name change from ImmunoCellular Therapeutics Ltd., to EOM Pharmaceutical Holdings, Inc.
-
This week money went towards more advanced rounds of financing for drugs and technology that have already shown a lot of promises.
-
EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger Agreement
12/2/2021
Combined company will operate as EOM Pharmaceuticals Holdings, Inc. advancing a pipeline of novel immunomodulatory agents including EOM613 currently in clinical trials in Brazil as a potential treatment for severely ill COVID-19 patients.
-
ImmunoCellular Therapeutics Announces Application for Continued Public Quoting on the Over-the-Counter (OTC) Market
6/28/2021
ImmunoCellular Therapeutics, Ltd., announced that the Company has taken steps to comply with amended Rule 15c2-11 under the Securities and Exchange Act which will be applicable in September 2021.
-
ImmunoCellular Therapeutics Announces Results of Special Meeting of Stockholders Held June 26, 2020
7/2/2020
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC), today announced that, based on the vote count following the Special Meeting of Stockholders held June 26 , 2020, stockholders voted in favor of the proposal to approve an amendment to the Company's Amended and Restated Certificate of Incorporation to effect a reverse stoc
-
ImmunoCellular Therapeutics Announces Settlement of Derivative Action Lawsuit
10/16/2019
The Court approved the settlement amount of one hundred forty-five thousand dollars ($145,000.00) to be paid by ImmunoCellular's insurer to Plaintiff's Counsel, and for a Service Award of one thousand dollars ($1,000.00) to be paid to Plaintiff from the Fee and Expense Award.
-
ImmunoCellular Therapeutics Announces Completion of Asset Purchase Transaction with Private Biotechnology Company
8/28/2019
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (OTC: IMUC) today announced receipt of payment of $500,000 in conjunction with the completion of a transaction for the purchase of substantially all of ImmunoCellular's remaining assets, including its preclinical and clinical programs, technology, intellectual property and know-how.
-
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
-
ImmunoCellular Therapeutics Announces Asset Purchase Agreement with Private Biotechnology Company
7/16/2019
ImmunoCellular Therapeutics, Ltd. announced an agreement with a privately held biotechnology company (the "Purchaser") for the purchase of substantially all of ImmunoCellular's remaining clinical and pre-clinical assets, including its preclinical and clinical programs, technology, intellectual property and know-how.
-
ImmunoCellular Announces Receipt of Notice of Noncompliance with The NYSE American Continued Listing Standards
10/17/2018
ImmunoCellular Therapeutics, Ltd. today announced that on October 16, 2018, the Company received notice from the NYSE American LLC ("NYSE American" or the "Exchange") that it has determined to commence proceedings to delist the Company's Common Stock (NYSE American: IMUC) and Listed Common Stock Warrants (NYSE American: IMUC.WS) from the Exchange.
-
ImmunoCellular Therapeutics Announces Delisting and Deregistration of Common Stock and Listed Common Stock Warrants
10/15/2018
Management Team to Transition to Consulting Roles in Effort to Streamline Operations and Manage Expenses
-
ImmunoCellular Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results
8/13/2018
Ongoing Exploration of Strategic Opportunities
-
ImmunoCellular Therapeutics Announces Agreement on Terms of Settlement of Federal Class Action Shareholder Lawsuit
7/19/2018
Settlement Will Be Paid By Company's Insurance Carrier
-
ImmunoCellular Therapeutics Announces Achievement of Next Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program
4/12/2018
ImmunoCellular Therapeutics, Ltd. announced today that it has been able to verify successful transfer of the selected T cell receptor genetic material into human hematopoietic stem cells.
-
ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2017 Financial Results
3/13/2018
ImmunoCellular Therapeutics, Ltd. announced financial results for the fourth quarter and full year ended December 31, 2017.
-
ImmunoCellular Therapeutics to Report Fourth Quarter and Full Year 2017 Financial Results on March 13, 2018
3/7/2018
ImmunoCellular Therapeutics, Ltd announced that it plans to report fourth quarter and full year 2017 financial results on Tuesday, March 13, 2018.
-
ImmunoCellular Therapeutics Announces Update on Financial Condition
2/14/2018
The Company ended 2017 with approximately $6.6 million in cash.
-
ImmunoCellular Therapeutics Achieves Key Milestone in Stem-to-T-Cell Research Immuno-Oncology Program
12/14/2017
The milestone represents an important step toward stimulating the patient's immune system to produce an unlimited supply of killer T cells that specifically target and destroy tumor cells with minimal side effects.
-
ImmunoCellular Therapeutics Announces Third Quarter 2017 Financial Results
11/22/2017
For the quarter ended September 30, 2017, research and development expenses were $2.8M compared to $4.6M during the quarter ended September 30, 2016.
-
ImmunoCellular Therapeutics to Report Third Quarter 2017 Financial Results on November 21, 2017
11/17/2017
The Company also plans to hold a conference call and webcast on that day at 5:00 pm ET to discuss the third quarter 2017 financial results and provide a business update.